| Lax Approval Requirements Yield Blockbusters That Don’t Work | Andy Smith | 03/13/20 | National |
| West Coast Bio Roundup: CRISPR Patent, HCV Data, Verily Digs & More | Alex Lash | 02/19/16 | San Francisco |
| West Coast Biotech Roundup: Tandem, Pathway Genomics, Denali & More | Bruce V. Bigelow | 09/10/15 | San Diego |
| Bristol-Myers Makes $150M Bet on Promedior, Fibrosis Drug | Ben Fidler | 08/31/15 | Boston |
| West Coast Biotech Roundup: Hep C, 23andMe, Kite, Cash, Isis & More | Alex Lash | 01/08/15 | San Francisco |
| As Rival Sputters, FibroGen Heads to Nasdaq Via $146M IPO | Ben Fidler | 11/14/14 | San Francisco |
| West Coast Biotech Roundup: Illumina, Atara, Invitae, Canaan & More | Alex Lash | 10/17/14 | San Francisco |
| West Coast Biotech Roundup: Mapp Bio, Calico, Alder, VentiRx & More | Alex Lash | 09/04/14 | San Diego |
| West Coast Biotech Roundup: ARCH, Ebola, ViaCyte, Calithera & More | Alex Lash | 08/28/14 | San Francisco |
| Roche To Pay $8.3B For Intermune: Who’s Next In Pulmonary Fibrosis? | Alex Lash | 08/25/14 | San Francisco |
| East Coast Biotech Roundup: Sigal, Radius, SHIN-NY, & More | Ben Fidler | 02/28/14 | Boston |
| Enanta, No Longer Obscure, Seeks Slice of Big Hepatitis C Market | Ben Fidler | 01/24/14 | Boston |
| Genoa Pharma Aims To Satisfy Big Pharma’s Hunger for IPF Drugs | Luke Timmerman | 03/30/12 | San Diego |
| In a Detour From Device Strategy, Zogenix Edges Closer to New Drug Application | Bruce V. Bigelow | 10/27/11 | San Diego |
| Amira Pharma on How it Beat the Odds, and Sold an Early Stage Drug to Bristol-Myers for $325M | Luke Timmerman | 09/07/11 | San Diego |
| Stop the M&A Obsession: Biotech Needs More Companies to Stay Independent | Luke Timmerman | 07/18/11 | National |
| Plexxikon’s Big Payday, InterMune Wins EU Approval, UCSF’s $48M Windfall, & More Bay Area Life Sciences News | Luke Timmerman | 03/04/11 | San Francisco |
| InterMune Wins EU Approval | Luke Timmerman | 03/03/11 | San Francisco |
| Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease | Ryan McBride | 02/07/11 | Boston |
| Intermune Gets EU Advisory Nod; Shares Boom | Luke Timmerman | 12/17/10 | San Francisco |
| San Diego’s Zogenix Moving Fast to Commercialize Drug-and-Device Combo | Bruce V. Bigelow | 08/17/10 | San Diego |
| Vertex Maps Out Combo Drug Game Plan for Treating Hepatitis C | Luke Timmerman | 03/08/10 | Boston |
| Amira Mixes Small Biotech Irreverence, With Big Pharma Rigor, To Create New Lung Drugs | Luke Timmerman | 01/28/10 | San Diego |
| Amira’s Drug Discovery Team, Pioneers of Hit Asthma Treatment, Take Aim at Pulmonary Fibrosis | Luke Timmerman | 03/18/09 | San Diego |
| Vertex Gears up for Big Liver Disease Conference | Luke Timmerman | 10/29/08 | Boston |
| Targanta Aims to “Simplifi” Treatment of Deadly Bugs With Single-Shot Antibiotic | Luke Timmerman | 09/22/08 | Boston |
| Vertex Fending Off Competitors By Treating the Toughest Patients With Hepatitis C | Luke Timmerman | 09/09/08 | Boston |
